Acquisition Insight Recent acquisition by RTI International signals validation of MDA’s real-world evidence capabilities and potential for expanded contract opportunities with larger organizations seeking integrated GHEOR services.

Niche Expertise Specialization in chart studies across incidence, burden of illness, treatment patterns, outcomes, and patient-reported outcomes positions MDA to pitch end-to-end GHEOR studies to pharma and biotech firms designing trials and market access strategies.

Growth Potential Small to mid-size team with global reach and two decades of experience suggests opportunities with mid-market life sciences companies seeking agile, cost-effective GHEOR support and rapid project execution.

Tech Stack Fit Current technologies (Joomla, MooTools, jQuery, PHP) indicate potential for modernizing data collection and reporting platforms or integrating with clients’ analytics ecosystems to enhance chart study delivery.

Strategic Outreach Low revenue bracket (<$1M) combined with high-value services presents a chance to target startups and smaller biotechs with scalable GHEOR engagements, potentially expanding after RTI-backed credibility.